


HFA Clinical Trial in Heart Failure Course 2021

Scientific Program (HFA reserves the rights to alter the programme).

 Friday, 01st October

12:00 - 13:30	Onsite Lunch	90 min
	Onsite and Online	
13:30 - 13:40	<i>A. Coats (remote), G. Rosano, P. Seferovic</i> : Welcome from the HFA	10 min
13:40 - 13:50	<i>E. Jankowska, G. Savarese</i> : Logistic information of the meeting	10 min
13:50 – 14:40	Session 1: Clinical trials in Heart Failure: Old and new perspectives Chairperson: P. Seferovic	50 min
13:50 - 14:20	<i>A. Coats (remote)</i> : Where are we going to?	30 min
14:20 - 14:40	<i>P. Ponikowski</i> : Where do we come from?	20 min
14:40 - 16:10	Session 2: How to optimize the endpoint analyses in HF? Chairperson: F. Pinto	90 min
14:40 - 15:10	<i>G. Filippatos</i> : Clinical trial design in heart failure. Which end point, when?	30 min
15:10 - 15:40	<i>J. Gregson</i> : Hierarchical outcome analysis	30 min
15:40 - 16:10	<i>M. Metra</i> : Subgroup analyses	30 min
16:10 - 16:30	Break	20 min
16:30 - 17:30	Session 3: Registries and registry-based trials in HF Chairperson: K. Prasad (remote)	60 min
16:30 - 17:00	<i>G. Savarese</i> : Registry-based research in HF	30 min
17:00 - 17:30	<i>L. Lund (remote)</i> : Registry-based randomized controlled trials in HF	30 min
17:30 - 18:00	Session 4: Clinical trials in heart failure: regulatory aspects Chairperson: P. Ponikowski	30 min
17:30 - 18:00	<i>G. Rosano</i> : Regulatory aspects of clinical trials in HF	30 min
18:00 - 19:00	Session 5: Clinical trials in heart failure: Industry perspective Chairpersons: M. Lainscak, E. Jankowska, G. Filippatos	60 min
18:00 - 18:15	<i>Ola Vedin</i> : Point of view: Boehringer Ingelheim	15 min
18:15 - 18:30	<i>Matteo Papi (remote)</i> : Point of view: AstraZeneca	15 min
18:30 - 18:45	<i>Fabio Dorigotti</i> : Point of view: Vifor Pharma	15 min
18:45 - 19:00	<i>Claudio Gimpelewicz (remote)</i> : Point of view: Novartis	15 min
19:00 - 20:00	Break	60 min
20:00	Onsite Dinner	